Reproductive and Developmental Effects of Moxifloxacin on Female Mice and Embryos | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 2, Volume 17, Issue 1, October 2004, Page 12-19 PDF (262.42 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2004.18153 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Hanaa M. Roshdy | ||||
| Cell Biology Department, National Research Center Dokki, Cairo, Egypt | ||||
| Abstract | ||||
| Moxifloxacin (Avelox®) is a fluoroquinolone antibiotic with a broad spectrum of activity and bactericidal action. Moxifloxacin has in vitro activity against a wide range of Gram- positive and Gram-negative organisms. The safe use of moxifloxacin in human pregnancy has not been established. In order to evaluate the genotoxic and embryo toxic effects of (Avelox)® during pregnancy, Avelox was administrated orally to female mice with doses (8.7, 17 and 26 mg/kg/day) from 1 to 17 days of pregnancy. Caesarean sections were completed on gestation day 18 and complete fetal examinations and cytogenetic analysis were conducted. Decreases in the fetal body weights and increases in the external visceral and skeletal anomalies were found in all doses of (8.7, 17 and 26 mg) Avelox compared to the controls. Cytogenetic analysis in mothers and embryos revealed that all the tests doses produced chromosomal aberrations and micronuclei (MN) formations in a dose dependent manner compared to the controls. These results indicate that Avelox has a maternal and embryotoxic effects on the female mice and their embryos when administered with a recommended and above the recommended dose during pregnancy. | ||||
| Keywords | ||||
| Moxifloxacin; chromosomal aberrations – micronuclei – mice – embryos | ||||
|
Statistics Article View: 227 PDF Download: 434 |
||||
